A day after Sanofi and GlaxoSmithKline said their COVID-19 shot works well as a booster for other shot regimens, Valneva and Arcturus Therapeutics are adding to the chorus. Valneva's phase 1/2 results are from a test that used the biotech’s own shot as a primary course. VLA2001 showed “excellent” immune response after administration seven to eight months after a primary course of the same shot, according to a Thursday statement. The biotech said the shot “significantly” boosted immunity in the participants. Source: Fierce Biotech 16/12/2021